MX388699B - Formas cristalinas de cabotegravir de sodio - Google Patents

Formas cristalinas de cabotegravir de sodio

Info

Publication number
MX388699B
MX388699B MX2019009810A MX2019009810A MX388699B MX 388699 B MX388699 B MX 388699B MX 2019009810 A MX2019009810 A MX 2019009810A MX 2019009810 A MX2019009810 A MX 2019009810A MX 388699 B MX388699 B MX 388699B
Authority
MX
Mexico
Prior art keywords
crystalline forms
cabotegravir
sodium
pharmaceutical composition
relates
Prior art date
Application number
MX2019009810A
Other languages
English (en)
Other versions
MX2019009810A (es
Inventor
Andrea Thaler
Verena Adamer
Original Assignee
Viiv Healthcare Uk No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17156518.7A external-priority patent/EP3363802B1/en
Application filed by Viiv Healthcare Uk No 3 Ltd filed Critical Viiv Healthcare Uk No 3 Ltd
Publication of MX2019009810A publication Critical patent/MX2019009810A/es
Publication of MX388699B publication Critical patent/MX388699B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a formas cristalinas de cabotegravir de sodio y a método para su preparación. Además, la invención se relaciona a una composición farmacéutica que comprende una de las dichas formas cristalinas de cabotegravir de sodio, preferentemente en una cantidad predeterminada y/o efectiva, y por lo menos un excipiente farmacéutico aceptable. La composición farmacéutica de la presente invención se puede usar como medicamento, en específico para el tratamiento y/o profilaxis de infecciones virales tales como las infecciones de VIH.
MX2019009810A 2017-02-16 2018-01-25 Formas cristalinas de cabotegravir de sodio MX388699B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17156518.7A EP3363802B1 (en) 2017-02-16 2017-02-16 Crystalline form of cabotegravir sodium
EP17161414 2017-03-16
PCT/EP2018/051819 WO2018149608A1 (en) 2017-02-16 2018-01-25 Crystalline forms of cabotegravir sodium

Publications (2)

Publication Number Publication Date
MX2019009810A MX2019009810A (es) 2019-12-02
MX388699B true MX388699B (es) 2025-03-20

Family

ID=61168064

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009810A MX388699B (es) 2017-02-16 2018-01-25 Formas cristalinas de cabotegravir de sodio
MX2021015441A MX2021015441A (es) 2017-02-16 2019-08-15 Formas cristalinas de cabotegravir de sodio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015441A MX2021015441A (es) 2017-02-16 2019-08-15 Formas cristalinas de cabotegravir de sodio.

Country Status (8)

Country Link
US (3) US11040986B2 (es)
EP (1) EP3583107B1 (es)
CN (1) CN110582504A (es)
AU (2) AU2018221379B2 (es)
CA (1) CA3053202C (es)
MX (2) MX388699B (es)
RU (1) RU2019125378A (es)
WO (1) WO2018149608A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582504A (zh) * 2017-02-16 2019-12-17 桑多斯股份公司 卡博特韦钠的晶形
WO2023175386A2 (en) * 2021-10-08 2023-09-21 Laurus Labs Limited Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1740593T1 (sl) 2004-04-19 2016-08-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo polimorfne oblike I klopidogrel hidrogen sulfata
PL3372281T3 (pl) * 2005-04-28 2021-12-27 Viiv Healthcare Company Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN106866702B (zh) 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015177537A1 (en) 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
WO2018109786A1 (en) * 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
CN110582504A (zh) * 2017-02-16 2019-12-17 桑多斯股份公司 卡博特韦钠的晶形

Also Published As

Publication number Publication date
RU2019125378A (ru) 2021-03-16
US20250236630A1 (en) 2025-07-24
AU2018221379A1 (en) 2019-08-29
US11040986B2 (en) 2021-06-22
EP3583107A1 (en) 2019-12-25
EP3583107B1 (en) 2020-11-18
US20210300945A1 (en) 2021-09-30
RU2019125378A3 (es) 2021-03-16
CA3053202C (en) 2022-10-04
MX2019009810A (es) 2019-12-02
MX2021015441A (es) 2022-01-24
AU2022200513A1 (en) 2022-02-17
WO2018149608A1 (en) 2018-08-23
CN110582504A (zh) 2019-12-17
AU2018221379B2 (en) 2021-11-04
AU2022200513B2 (en) 2023-11-02
CA3053202A1 (en) 2018-08-23
US20200385401A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
PH12015501156A1 (en) Pharmaceutical compositions
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
BR112018005904A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
IN2013MU03583A (es)
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
BR112018005870A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
MX2020008360A (es) Forma cristalina de bictegravir sodico.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
CO2020000292A2 (es) Preparación medicinal combinada para tratar infecciones virales
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
BR112018000251A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.
BR112017014295A2 (pt) composição farmacêutica.
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия